000 04006cam a2200625 a 4500
001 ocn666931928
003 OCoLC
005 20221128211200.0
006 m d
007 cr cn|||||||||
008 100929s2009 enka ob 001 0 eng d
040 _aIDEBK
_beng
_epn
_cIDEBK
_dN$T
_dEBLCP
_dOCLCQ
_dYDXCP
_dOCLCQ
_dMHW
_dOCLCF
_dUKDOC
_dOCLCQ
_dNLGGC
_dOCLCQ
_dD6H
_dAGLDB
_dZ5A
_dOCLCQ
_dVTS
_dTOF
_dAU@
_dJBG
_dWYU
_dSTF
_dM8D
_dOCLCO
_dOCLCQ
_dOCLCA
_dOCLCQ
_dUKAHL
_dOCLCQ
_dOCLCO
019 _a416480892
_a815776118
_a965934893
020 _a9781846926013
_q(electronic bk.)
020 _a1846926017
_q(electronic bk.)
020 _a1282093916
020 _a9781282093911
020 _a9781846920349
020 _a1846920345
035 _a277322
_b(N$T)
035 _a(OCoLC)666931928
_z(OCoLC)416480892
_z(OCoLC)815776118
_z(OCoLC)965934893
060 4 _aWD 200.5.H8
_bL762 2009
072 7 _aMED
_x027000
_2bisacsh
072 7 _aMED
_x060000
_2bisacsh
072 7 _aK
_2bicssc
049 _aMAIN
245 0 0 _aLipid disorders
_c
_h[E-Book]
246 1 4 _aTherapeutic strategies in lipid disorders
260 _aOxford :
_bClinical,
_c2009.
300 _a1 online resource (ix, 284 pages) :
_billustrations
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
490 1 _aTherapeutic strategies
504 _aIncludes bibliographical references and index.
520 _aLipid disorders are now recognised as a diverse group of diseases that together represent one of the foremost risk factors for cardiovascular disease in general. Frequently present in association with other chronic illnesses such as hypertension, diabetes, and obesity, lipid disorders are a key therapeutic target for clinicians. This book examines the causes and consequences of lipid disorders, and the treatments available. Special chapters are dedicated to the associations between lipid disorders and other conditions, for example cerebrovascular disease and heart failure, as well as the wider.
505 0 _aEditorand Contributors; Foreword; Chapter 1: A global view of cardiovascular risk factors; Chapter 2: Low-density lipoprotein cholesterol as a therapeutic target; Chapter 3: High-density lipoprotein as a therapeutic target; Chapter 4: Apolipoprotein B in the therapy of atherogenic dyslipoproteinaemias; Chapter 5: Management of coronary heart disease patients; Chapter 6: Stroke and transient ischaemic attack prevention; Chapter 7: Diabetes and the metabolic syndrome; Chapter 8: Hypertension; Chapter 9: Treatment of familial hypercholesterolaemia.
505 8 _aChapter 10: Lipid lowering in chronic kidney diseaseChapter 11: Statins and heart failure; Chapter 12: Absolute risk assessment in the general population; Chapter 13: Pleiotropic effects of statins and potential new indications; Chapter 14: The role of imaging endpoints in clinical trials; Chapter 15: Biomarkers in cardiovascular disease; Chapter 16: Novel lipid-modifying agents; Chapter 17: The enhanced evidence base and translation into improved outcomes; Abbreviations; Index.
590 _aWorldCat record variable field(s) change: 650
650 0 _aLipids
_xMetabolism
_xDisorders.
650 0 _aLipids
_xMetabolism.
650 2 _aDyslipidemias
_xtherapy
650 2 _aLipid Metabolism
700 1 _aTonkin, Andrew M.
830 0 _aTherapeutic strategies.
856 4 0 _uhttps://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=277322
_yKingston Hospital NHS Foundation Trust OpenAthens account holders click here for access
938 _a123Library
_b123L
_n1866
938 _aAskews and Holts Library Services
_bASKH
_nAH28329618
938 _aProQuest Ebook Central
_bEBLB
_nEBL434065
938 _aEBSCOhost
_bEBSC
_n277322
938 _aProQuest MyiLibrary Digital eBook Collection
_bIDEB
_n209391
938 _aYBP Library Services
_bYANK
_n3032031
942 _n0
994 _a92
_bN$T
999 _c89590
_d89590